AE | Grade AE in dose cohort | Grade 3 and above # affected/% | ||||
10 µg | 20 µg | 33 µg | 50 µg | 70 µg | ||
ALP, high | 3, 3, 4 | 3 | 4/19.0 | |||
Dyspnea | 4 | 4 | 2/9.5 | |||
Potassium, high | 3 | 3 | 2/9.5 | |||
Soft tissue necrosis | 3*, 3* | 2/9.5 | ||||
Acidosis | 3 | 1/4.7 | ||||
ALT, high | 3* | 1/4.7 | ||||
AST, high | 3* | 1/4.7 | ||||
Dehydration | 4 | 1/4.7 | ||||
Diarrhea | 3 | 1/4.7 | ||||
Hypoxia | 4 | 1/4.7 | ||||
Lethargy/fatigue | 3 | 1/4.7 | ||||
Lymph leakage | 3 | 1/4.7 | ||||
Peritonitis, non-septic | 3 | 1/4.7 | ||||
Total | 5 | 6 | 1 | 0 | 7 | 19 |
*Attribution possibly related to treatment. All others attributed to disease progression.
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase.